Annual General Meeting 2024

Invitation to the Annual General Meeting on 12 March 2024 (PDF)

Voting results (PDF)

Item 1: Submission of the adopted separate annual financial statements and of the approved consolidated financial statements of BRAIN Biotech AG for the fiscal year ending 30 September 2023, the separate management report and the Group management report for the fiscal year from 1 October 2022 until 30 September 2023 with the explanatory reports relating to disclosures pursuant to Sections 289a and 315a of the German Commercial Code (HGB), as well as the report by the Supervisory Board for the fiscal year from 1 October 2022 to 30 September 2023

Annual Report FY 2022/23 (PDF)

Group management report and Consolidated financial statements (from AR 2022/23) (PDF)

Company’s annual financial statement and management report 2022/23 (German version only) (PDF)

Explanatory report by the Executive Board regarding the information pursuant to §§ 289a, 315a of the German Commercial Code (HGB) for Fiscal Year 2022/23 (PDF)

Item 2: Resolution concerning the ratification of the actions of the Management Board for the fiscal year from 1 October 2022 to 30 September 2023

The Management and Supervisory boards propose that the actions of the Management Board members holding office during the fiscal year from 1 October 2022 to 30 September 2023 be ratified for this period.

Item 3: Resolution concerning the ratification of the actions of the Supervisory Board for the fiscal year from 1 October 2022 to 30 September 2023

The Management and Supervisory boards propose that the actions of the Supervisory Board members holding office during the fiscal year from 1 October 2022 to 30 September 2023 be ratified for this period.

Item 4: Election of the auditor of the separate financial statements and of the auditor of the consolidated financial statements for the fiscal year from 1 October 2023 to 30 September 2024

Pursuant to the recommendation of its Audit Committee, the Supervisory Board proposes electing 

Baker Tilly GmbH & Co KG Wirtschaftsprüfungsgesellschaft (Düsseldorf) 

to be the auditor of the separate and consolidated financial statements for the fiscal year from 1 October 2023 to 30 September 2024.

Item 4 in full wording (PDF)

Item 5: Resolution to approve the conclusion of an agreement relating to the establishment of a typical silent partnership between BRAIN Biotech AG and Hessen Kapital I GmbH with contributed capital of € 2,000,000.0

Item 5 in full wording (PDF)

Agreement concerning the establishment of a typical silent partnership with Hessen Kapital I, € 2.0 Million (German only) (PDF)

C.1 Further notes relating to agenda item 5 regarding the establishment of a typical silent partnership between BRAIN Biotech AG and Hessen Kapital I GmbH with contributed capital of € 2.0 Million (PDF)

Annual financial statements and the management reports of BRAIN Biotech AG for the last three fiscal years (German only) (PDF)

Annual financial statements and the management reports of Hessen Kapital I GmbH for the last three fiscal years (German only) (PDF)

Written report of the Management Board of BRAIN Biotech AG pursuant to Section 293 a AktG regarding Hessen Kapital I, € 2.0 Million (German only) (PDF)

Written report of the contract auditor concerning the contract audit pursuant to Section 293 e AktG, Hessen Kapital I, € 2.0 Million (German only) (PDF)

Item 6: Resolution to approve the conclusion of an agreement relating to the establishment of a typical silent partnership between BRAIN Biotech AG and Hessen Kapital I GmbH with contributed capital of € 1,500,000.00

Item 6 in full wording (PDF)

Agreement concerning the establishment of a typical silent partnership with Hessen Kapital I, € 1.5 Million (German only) (PDF)

C.2 Further notes relating to agenda item 6 regarding the establishment of a typical silent partnership between BRAIN Biotech AG and Hessen Kapital I GmbH with contributed capital of € 1.5 Million. (PDF)

Annual financial statements and the management reports of BRAIN Biotech AG for the last three fiscal years (German only) (PDF)

Annual financial statements and the management reports of Hessen Kapital I GmbH for the last three fiscal years (German only) (PDF)

Written report of the Management Board of BRAIN Biotech AG pursuant to Section 293 a AktG regarding Hessen Kapital I, € 1.5 Million (German only) (PDF)

Written report of the contract auditor concerning the contract audit pursuant to Section 293 e AktG, Hessen Kapital I, € 1.5 Million (German only) (PDF)

Item 7: Resolution to approve the conclusion of an agreement relating to the establishment of a typical silent partnership between BRAIN Biotech AG and MBG H Mittelständische Beteiligungsgesellschaft Hessen mbH with contributed capital of € 1,500,000.00

Item 7 in full wording (PDF)

Agreement concerning the establishment of a typical silent partnership with MBG H, € 1.5 Million (German only) (PDF)

C.3 Further notes relating to agenda item 7 regarding the establishment of a typical silent partnership between BRAIN Biotech AG and MBG H Mittelständische Beteiligungsgesellschaft Hessen mbH with contributed capital of € 1.5 Million (PDF)

Annual financial statements and the management reports of BRAIN Biotech AG for the last three fiscal years (German only) (PDF)

Annual financial statements and the management reports of MBG H for the last three fiscal years (German only) (PDF)

Written report of the Management Board of BRAIN Biotech AG pursuant to Section 293 a AktG regarding MBG H, € 1.5 Million (German only) (PDF)

Written report of the contract auditor concerning the contract audit pursuant to Section 293 e AktG, MBG H, € 1.5 Million (German only) (PDF)

Item 8: Resolution concerning the approval of the Compensation Report

The Management and Supervisory boards propose that the Compensation Report for the 2022/23 fiscal year, prepared and audited in accordance with Section 162 AktG, be approved.

Item 8 in full wording (PDF)

Compensation Report and Auditor's Report (German version only) (PDF)